Last reviewed · How we verify
Prednisone alone
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Adrenocortical insufficiency, Rheumatoid arthritis, Systemic lupus erythematosus.
At a glance
| Generic name | Prednisone alone |
|---|---|
| Also known as | prednisolone |
| Sponsor | Guangdong Provincial People's Hospital |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Prednisone enters cells and binds to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The drug has broad anti-inflammatory and immunosuppressive effects across multiple cell types.
Approved indications
- Adrenocortical insufficiency
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Asthma
- Chronic obstructive pulmonary disease exacerbations
- Allergic reactions
- Inflammatory bowel disease
- Autoimmune hemolytic anemia
- Thrombocytopenia
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Increased appetite
- Mood changes (irritability, anxiety)
- Osteoporosis (with chronic use)
- Immunosuppression / increased infection risk
- Gastrointestinal upset
- Acne
- Fluid retention
Key clinical trials
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (PHASE2)
- M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) (PHASE1)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone alone CI brief — competitive landscape report
- Prednisone alone updates RSS · CI watch RSS
- Guangdong Provincial People's Hospital portfolio CI